Kalobios Pharmaceuticals Inc (KBIO) 11.03 $KBIO
KaloBios Pharmaceuticals, Inc. Withdraws Appeal on Nasdaq Delisting
PR Newswire - Tue Jan 12, 3:15PM CST
KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) (the "Company"
, today announced that it has decided to withdraw its appeal of the decision by the Nasdaq listing qualifications staff to delist the Company's securities from the Nasdaq stock exchange.
KBIO: 11.03 (-12.56)
Nasdaq to Suspend KaloBios Pharmaceuticals, Inc. on January 13, 2016
GlobeNewswire - Tue Jan 12, 8:45AM CST
The Nasdaq Stock Market ("Nasdaq" announced today that, pursuant to Listing Rule 5815(a)(1)(
, KaloBios Pharmaceuticals, Inc. (Nasdaq:KBIO) will be suspended from Nasdaq effective January 13, 2016.
KBIO: 11.03 (-12.56), NDAQ: 65.58 (-0.08)
SHAREHOLDER NOTICE: Khang & Khang LLP Announces the Filing of a Securities Class Action Lawsuit against KaloBios Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $50,000 to Contact the Firm
BusinessWire - Mon Jan 11, 8:10PM CST
Khang & Khang LLP (the "Firm" announces that a class action lawsuit has been filed against KaloBios Pharmaceuticals, Inc. ("KaloBios" or the "Company" (Nasdaq: KBIO). Investors who purchased or otherwise acquired shares between November 19, 2015 and December 17, 2015, inclusive (the "Class Period" are encouraged to contact the Firm prior to the February 16, 2016, lead plaintiff motion deadline.
KBIO: 11.03 (-12.56)
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in KaloBios Pharmaceuticals, Inc. to Contact Brower Piven Before the Lead Plaintiff Deadline in Class Action Lawsuit - KBIO
GlobeNewswire - Mon Jan 11, 7:30PM CST
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Northern District of California on behalf of purchasers of KaloBios Pharmaceuticals, Inc. (Nasdaq:KBIO) ("KaloBios" or the "Company" securities during the period between November 19, 2015 and December 17, 2015, inclusive (the "Class Period". Investors who wish to become proactively involved in the litigation have until February 16, 2016 to seek appointment as lead plaintiff.
KBIO: 11.03 (-12.56)
KaloBios Pharmaceuticals, Inc. Announces Board Changes and New Appointments
PR Newswire - Mon Jan 11, 10:46AM CST
KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO)(the "Company", today announced that on January 7, 2016, Ronald Barliant and Dr. Cameron Durrant MD, MBA, were elected as independent directors to the board of directors (the "Board" of the Company, with Dr. Durrant named as Chairman of the Board. In addition, on January 7, 2016, Michael Harrison resigned from the Board.
KBIO: 11.03 (-12.56)
Ryan & Maniskas, LLP Files Class Action Lawsuit Against KaloBios Pharmaceuticals, Inc.
PR Newswire - Fri Jan 08, 7:30PM CST
Ryan & Maniskas, LLP announces it has filed a class action lawsuit has been filed in the United States District Court for the Northern District of California against KaloBios Pharmaceuticals, Inc. ("KaloBios" or the "Company" (NASDAQ: KBIO) on behalf of investors who purchased or otherwise acquired the common stock of the Company during the period from November 19, 2015 through December 17, 2015 (the "Class Period).
KBIO: 11.03 (-12.56)
IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces The Filing Of A Securities Class Action Lawsuit Against KaloBios Pharmaceuticals, Inc. And Encourages Investors With Losses in Excess of $50,000 To Contact The Firm
BusinessWire - Wed Jan 06, 1:24PM CST
Khang & Khang LLP (the "Firm" announces that a class action lawsuit has been filed against KaloBios Pharmaceuticals, Inc. ("KaloBios" or the "Company" (Nasdaq: KBIO). Investors who purchased or otherwise acquired shares between November 19, 2015 and December 17, 2015, inclusive (the "Class Period" are encouraged to contact the Firm prior to the February 16, 2016, lead plaintiff motion deadline.
KBIO: 11.03 (-12.56)
KALOBIOS PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe and Powers Taylor Investigate Possible Breaches of Fiduciary Duty by Officers and Directors
BusinessWire - Wed Jan 06, 11:38AM CST
Former United States Securities and Exchange Commission attorney Willie Briscoe, founder of The Briscoe Law Firm, PLLC, and the securities litigation firm of Powers Taylor LLP announce that a federal class action lawsuit has been filed in the United States District Court, Northern District of California against KaloBios Pharmaceuticals, Inc. ("KaloBios" (NASDAQ: KBIO) and several officers and directors for acts taken during the period of November 19, 2015 and December 17, 2015 (the "Class Period".
KBIO: 11.03 (-12.56)
Investor Alert: Brower Piven Encourages Shareholders Who Have Losses in Excess of $100,000 from Investment in KaloBios Pharmaceuticals, Inc. to Contact Brower Piven before the Lead Plaintiff Deadline in Class Action Lawsuit
BusinessWire - Mon Jan 04, 4:39PM CST
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Northern District of California on behalf of purchasers of KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) ("KaloBios" or the "Company" securities during the period between November 19, 2015 and December 17, 2015, inclusive (the "Class Period". Investors who wish to become proactively involved in the litigation have until February 16, 2016 to seek appointment as lead plaintiff.
KBIO: 11.03 (-12.56)
DEADLINE APPROACHING: Goldberg Law PC Announces Securities Class Action Lawsuit Against KaloBios Pharmaceuticals, Inc. And Reminds Investors With Losses In Excess of $100,000 To Contact The Firm
BusinessWire - Fri Jan 01, 2:08PM CST
Goldberg Law PC (www.Goldberglawpc.com) announces that a class action lawsuit has been filed against KaloBios Pharmaceuticals, Inc. ("KaloBios" or the "Company" (NASDAQ:KBIO). Investors who purchased or otherwise acquired shares between November 19, 2015 and December 17, 2015, inclusive (the "Class Period", are encouraged to contact the firm in advance of the February 16, 2016, lead plaintiff motion deadline.
KBIO: 11.03 (-12.56)
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against KaloBios Pharmaceuticals, Inc. and Certain Officers - KBIO
GlobeNewswire - Thu Dec 31, 12:30PM CST
Pomerantz LLP announces that a class action lawsuit has been filed against KaloBios Pharmaceuticals, Inc. ("KaloBios" or the "Company" (NASDAQ:KBIO), and certain of its officers. The class action, filed in United States District Court, Northern District of California, and docketed under 15-cv-06331, is on behalf of a class consisting of all persons or entities who purchased KaloBios securities between November 19, 2015 and December 17, 2015 inclusive (the "Class Period". This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the "Exchange Act".
KBIO: 11.03 (-12.56)
KaloBios Pharmaceuticals, Inc. Notified by Nasdaq Stock Market of Additional Bases for Delisting
PR Newswire - Thu Dec 31, 9:57AM CST
KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO)(the "Company", today announced that on December 30, 2015, it received a letter from The NASDAQ Stock Market LLC ("Nasdaq" concerning the delisting proceedings previously disclosed by the Company in a filing with the Securities and Exchange Commission on December 23, 2015. The letter notified the Company that the Nasdaq Listing Qualification Staff (the "Nasdaq Staff" has determined that the Company's filing for protection under Chapter 11 of Title 11 of the U.S. Bankruptcy Code on December 29, 2015 constitutes a separate and additional basis for delisting the Company's securities under Listing Rules 5101, 5110(b), and IM-5101-1. Additionally, the letter stated that the resignations of Tom Fernandez and Marek Biestek as members of the Company's board of directors on December 27, 2015 resulted in the Company having only one remaining member on its audit committee, which also serves as a separate and additional basis for delisting the Company's securities under Listing Rule 5605(c)(2)(A).
KBIO: 11.03 (-12.56)
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Investigation of KaloBios Pharmaceuticals, Inc. (KBIO)
ACCESSWIRE - Thu Dec 31, 9:00AM CST
NEW YORK, NY / ACCESSWIRE / December 31, 2015 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of KaloBios Pharmaceuticals, Inc. ("KaloBios" or the "Company" (NASDAQ: KBIO). Such investors are advised to contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz at info@bgandg.com or 212-697-6484.
KBIO: 11.03 (-12.56)
KaloBios Pharmaceuticals Files For Chapter 11 Bankruptcy After Shkreli Arrest
Madeleine Johnson - Zacks Investment Research - Wed Dec 30, 4:19PM CST
On Tuesday, biotechnology company KaloBios Pharmaceuticals Inc (KBIO) filed for Chapter 11 bankruptcy after a turbulent past month, all thanks to Chief Executive Martin Shkreli.
KBIO: 11.03 (-12.56)
KaloBios Pharmaceuticals, Inc. Files For Chapter 11 Bankruptcy Protection
PR Newswire - Wed Dec 30, 10:20AM CST
KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO)(the "Company", today announced that on December 29, 2015, it filed a voluntary petition for bankruptcy protection under Chapter 11 of Title 11 of the United States Bankruptcy Code (the "Bankruptcy Code". The filing was made in the United States Bankruptcy Court for the District of Delaware (the "Bankruptcy Court" (Case No. 15-12628).
KBIO: 11.03 (-12.56)
KaloBios Pharmaceuticals, Inc. Announces Submission of Request for Appeal of Nasdaq Delisting
PR Newswire - Tue Dec 29, 11:29AM CST
KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) (the "Company" today announced that on December 28, 2015, the Company submitted a request to Nasdaq requesting an appeal of Nasdaq's decision to delist the Company's securities. A hearing on the Company's appeal has been scheduled for February 25, 2016.
KBIO: 11.03 (-12.56)
IMPORTANT SHAREHOLDER ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit against KaloBios Pharmaceuticals, Inc. and Reminds Investors to Contact the Firm
BusinessWire - Mon Dec 28, 11:57AM CST
Goldberg Law PC (www.Goldberglawpc.com) announces that a class action lawsuit has been filed against KaloBios Pharmaceuticals, Inc. ("KaloBios" or the "Company" (NASDAQ: KBIO). Investors who purchased or otherwise acquired shares between November 19, 2015 and December 17, 2015, inclusive (the "Class Period", are encouraged to contact the firm in advance of the February 16, 2016, lead plaintiff motion deadline.
KBIO: 11.03 (-12.56)
Resignations at KaloBios After Shkreli Scandal
Andrew Steele - Zacks Investment Research - Wed Dec 23, 5:51PM CST
KaloBios has its CFO and accounting firm resign just a week after CEO Martin Shkreli was arrested for fraud. What does this mean for the pharmaceutical company?
KBIO: 11.03 (-12.56)
KaloBios Pharmaceuticals, Inc. Notified by Nasdaq Stock Market of Delisting
PR Newswire - Wed Dec 23, 3:30PM CST
KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) (the "Company", today announced that on December 18, 2015, it received a letter from the Nasdaq Listing Qualification Staff advising the Company that Nasdaq has determined to delist the Company's securities pursuant to its discretionary authority under Nasdaq Listing Rule 5101. Nasdaq's letter to the Company cited a number of reasons for their decision, including the recent criminal indictment and arrest of Martin Shkreli, the Company's controlling shareholder, former Chairman and former Chief Executive Officer, based on allegations of securities fraud, among other things, as well as the arrest and indictment of Evan Greebel, the Company's former outside counsel, based on similar allegations, and a civil complaint from the U.S. Securities and Exchange Commission filed against Mr. Shkreli and Mr. Greebel based on similar allegations. Nasdaq cited an additional basis for delisting based on the Company non-compliance with the filing requirements forth in the Nasdaq's Listing Rule 5250(c)(1) because it has not filed its Quarterly Report on Form 10-Q for the period ended September 30, 2015.
KBIO: 11.03 (-12.56)
EQUITY ALERT: Rosen Law Firm Announces the Filing of a Securities Class Action Lawsuit Against KaloBios Pharmaceuticals, Inc. - KBIO
BusinessWire - Wed Dec 23, 2:53PM CST
Rosen Law Firm, a global investor rights law firm, announces that a class action lawsuit has been filed on behalf of purchasers of KaloBios Pharmaceuticals, Inc. (NASDAQ:KBIO) securities from November 19, 2015 through December 17, 2015, all dates inclusive (the "Class Period". The lawsuit seeks to recover damages for KaloBios investors under the federal securities laws.
KBIO: 11.03 (-12.56)
KaloBios Pharmaceuticals, Inc. Withdraws Appeal on Nasdaq Delisting
PR Newswire - Tue Jan 12, 3:15PM CST
KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) (the "Company"
, today announced that it has decided to withdraw its appeal of the decision by the Nasdaq listing qualifications staff to delist the Company's securities from the Nasdaq stock exchange. KBIO: 11.03 (-12.56)
Nasdaq to Suspend KaloBios Pharmaceuticals, Inc. on January 13, 2016
GlobeNewswire - Tue Jan 12, 8:45AM CST
The Nasdaq Stock Market ("Nasdaq"
announced today that, pursuant to Listing Rule 5815(a)(1)(, KaloBios Pharmaceuticals, Inc. (Nasdaq:KBIO) will be suspended from Nasdaq effective January 13, 2016. KBIO: 11.03 (-12.56), NDAQ: 65.58 (-0.08)
SHAREHOLDER NOTICE: Khang & Khang LLP Announces the Filing of a Securities Class Action Lawsuit against KaloBios Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $50,000 to Contact the Firm
BusinessWire - Mon Jan 11, 8:10PM CST
Khang & Khang LLP (the "Firm"
announces that a class action lawsuit has been filed against KaloBios Pharmaceuticals, Inc. ("KaloBios" or the "Company" (Nasdaq: KBIO). Investors who purchased or otherwise acquired shares between November 19, 2015 and December 17, 2015, inclusive (the "Class Period" are encouraged to contact the Firm prior to the February 16, 2016, lead plaintiff motion deadline. KBIO: 11.03 (-12.56)
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in KaloBios Pharmaceuticals, Inc. to Contact Brower Piven Before the Lead Plaintiff Deadline in Class Action Lawsuit - KBIO
GlobeNewswire - Mon Jan 11, 7:30PM CST
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Northern District of California on behalf of purchasers of KaloBios Pharmaceuticals, Inc. (Nasdaq:KBIO) ("KaloBios" or the "Company"
securities during the period between November 19, 2015 and December 17, 2015, inclusive (the "Class Period". Investors who wish to become proactively involved in the litigation have until February 16, 2016 to seek appointment as lead plaintiff. KBIO: 11.03 (-12.56)
KaloBios Pharmaceuticals, Inc. Announces Board Changes and New Appointments
PR Newswire - Mon Jan 11, 10:46AM CST
KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO)(the "Company"
, today announced that on January 7, 2016, Ronald Barliant and Dr. Cameron Durrant MD, MBA, were elected as independent directors to the board of directors (the "Board" of the Company, with Dr. Durrant named as Chairman of the Board. In addition, on January 7, 2016, Michael Harrison resigned from the Board. KBIO: 11.03 (-12.56)
Ryan & Maniskas, LLP Files Class Action Lawsuit Against KaloBios Pharmaceuticals, Inc.
PR Newswire - Fri Jan 08, 7:30PM CST
Ryan & Maniskas, LLP announces it has filed a class action lawsuit has been filed in the United States District Court for the Northern District of California against KaloBios Pharmaceuticals, Inc. ("KaloBios" or the "Company"
(NASDAQ: KBIO) on behalf of investors who purchased or otherwise acquired the common stock of the Company during the period from November 19, 2015 through December 17, 2015 (the "Class Period). KBIO: 11.03 (-12.56)
IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces The Filing Of A Securities Class Action Lawsuit Against KaloBios Pharmaceuticals, Inc. And Encourages Investors With Losses in Excess of $50,000 To Contact The Firm
BusinessWire - Wed Jan 06, 1:24PM CST
Khang & Khang LLP (the "Firm"
announces that a class action lawsuit has been filed against KaloBios Pharmaceuticals, Inc. ("KaloBios" or the "Company" (Nasdaq: KBIO). Investors who purchased or otherwise acquired shares between November 19, 2015 and December 17, 2015, inclusive (the "Class Period" are encouraged to contact the Firm prior to the February 16, 2016, lead plaintiff motion deadline. KBIO: 11.03 (-12.56)
KALOBIOS PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe and Powers Taylor Investigate Possible Breaches of Fiduciary Duty by Officers and Directors
BusinessWire - Wed Jan 06, 11:38AM CST
Former United States Securities and Exchange Commission attorney Willie Briscoe, founder of The Briscoe Law Firm, PLLC, and the securities litigation firm of Powers Taylor LLP announce that a federal class action lawsuit has been filed in the United States District Court, Northern District of California against KaloBios Pharmaceuticals, Inc. ("KaloBios"
(NASDAQ: KBIO) and several officers and directors for acts taken during the period of November 19, 2015 and December 17, 2015 (the "Class Period". KBIO: 11.03 (-12.56)
Investor Alert: Brower Piven Encourages Shareholders Who Have Losses in Excess of $100,000 from Investment in KaloBios Pharmaceuticals, Inc. to Contact Brower Piven before the Lead Plaintiff Deadline in Class Action Lawsuit
BusinessWire - Mon Jan 04, 4:39PM CST
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Northern District of California on behalf of purchasers of KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) ("KaloBios" or the "Company"
securities during the period between November 19, 2015 and December 17, 2015, inclusive (the "Class Period". Investors who wish to become proactively involved in the litigation have until February 16, 2016 to seek appointment as lead plaintiff. KBIO: 11.03 (-12.56)
DEADLINE APPROACHING: Goldberg Law PC Announces Securities Class Action Lawsuit Against KaloBios Pharmaceuticals, Inc. And Reminds Investors With Losses In Excess of $100,000 To Contact The Firm
BusinessWire - Fri Jan 01, 2:08PM CST
Goldberg Law PC (www.Goldberglawpc.com) announces that a class action lawsuit has been filed against KaloBios Pharmaceuticals, Inc. ("KaloBios" or the "Company"
(NASDAQ:KBIO). Investors who purchased or otherwise acquired shares between November 19, 2015 and December 17, 2015, inclusive (the "Class Period", are encouraged to contact the firm in advance of the February 16, 2016, lead plaintiff motion deadline. KBIO: 11.03 (-12.56)
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against KaloBios Pharmaceuticals, Inc. and Certain Officers - KBIO
GlobeNewswire - Thu Dec 31, 12:30PM CST
Pomerantz LLP announces that a class action lawsuit has been filed against KaloBios Pharmaceuticals, Inc. ("KaloBios" or the "Company"
(NASDAQ:KBIO), and certain of its officers. The class action, filed in United States District Court, Northern District of California, and docketed under 15-cv-06331, is on behalf of a class consisting of all persons or entities who purchased KaloBios securities between November 19, 2015 and December 17, 2015 inclusive (the "Class Period". This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the "Exchange Act". KBIO: 11.03 (-12.56)
KaloBios Pharmaceuticals, Inc. Notified by Nasdaq Stock Market of Additional Bases for Delisting
PR Newswire - Thu Dec 31, 9:57AM CST
KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO)(the "Company"
, today announced that on December 30, 2015, it received a letter from The NASDAQ Stock Market LLC ("Nasdaq" concerning the delisting proceedings previously disclosed by the Company in a filing with the Securities and Exchange Commission on December 23, 2015. The letter notified the Company that the Nasdaq Listing Qualification Staff (the "Nasdaq Staff" has determined that the Company's filing for protection under Chapter 11 of Title 11 of the U.S. Bankruptcy Code on December 29, 2015 constitutes a separate and additional basis for delisting the Company's securities under Listing Rules 5101, 5110(b), and IM-5101-1. Additionally, the letter stated that the resignations of Tom Fernandez and Marek Biestek as members of the Company's board of directors on December 27, 2015 resulted in the Company having only one remaining member on its audit committee, which also serves as a separate and additional basis for delisting the Company's securities under Listing Rule 5605(c)(2)(A). KBIO: 11.03 (-12.56)
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Investigation of KaloBios Pharmaceuticals, Inc. (KBIO)
ACCESSWIRE - Thu Dec 31, 9:00AM CST
NEW YORK, NY / ACCESSWIRE / December 31, 2015 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of KaloBios Pharmaceuticals, Inc. ("KaloBios" or the "Company"
(NASDAQ: KBIO). Such investors are advised to contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz at info@bgandg.com or 212-697-6484. KBIO: 11.03 (-12.56)
KaloBios Pharmaceuticals Files For Chapter 11 Bankruptcy After Shkreli Arrest
Madeleine Johnson - Zacks Investment Research - Wed Dec 30, 4:19PM CST
On Tuesday, biotechnology company KaloBios Pharmaceuticals Inc (KBIO) filed for Chapter 11 bankruptcy after a turbulent past month, all thanks to Chief Executive Martin Shkreli.
KBIO: 11.03 (-12.56)
KaloBios Pharmaceuticals, Inc. Files For Chapter 11 Bankruptcy Protection
PR Newswire - Wed Dec 30, 10:20AM CST
KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO)(the "Company"
, today announced that on December 29, 2015, it filed a voluntary petition for bankruptcy protection under Chapter 11 of Title 11 of the United States Bankruptcy Code (the "Bankruptcy Code". The filing was made in the United States Bankruptcy Court for the District of Delaware (the "Bankruptcy Court" (Case No. 15-12628). KBIO: 11.03 (-12.56)
KaloBios Pharmaceuticals, Inc. Announces Submission of Request for Appeal of Nasdaq Delisting
PR Newswire - Tue Dec 29, 11:29AM CST
KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) (the "Company"
today announced that on December 28, 2015, the Company submitted a request to Nasdaq requesting an appeal of Nasdaq's decision to delist the Company's securities. A hearing on the Company's appeal has been scheduled for February 25, 2016. KBIO: 11.03 (-12.56)
IMPORTANT SHAREHOLDER ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit against KaloBios Pharmaceuticals, Inc. and Reminds Investors to Contact the Firm
BusinessWire - Mon Dec 28, 11:57AM CST
Goldberg Law PC (www.Goldberglawpc.com) announces that a class action lawsuit has been filed against KaloBios Pharmaceuticals, Inc. ("KaloBios" or the "Company"
(NASDAQ: KBIO). Investors who purchased or otherwise acquired shares between November 19, 2015 and December 17, 2015, inclusive (the "Class Period", are encouraged to contact the firm in advance of the February 16, 2016, lead plaintiff motion deadline. KBIO: 11.03 (-12.56)
Resignations at KaloBios After Shkreli Scandal
Andrew Steele - Zacks Investment Research - Wed Dec 23, 5:51PM CST
KaloBios has its CFO and accounting firm resign just a week after CEO Martin Shkreli was arrested for fraud. What does this mean for the pharmaceutical company?
KBIO: 11.03 (-12.56)
KaloBios Pharmaceuticals, Inc. Notified by Nasdaq Stock Market of Delisting
PR Newswire - Wed Dec 23, 3:30PM CST
KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) (the "Company"
, today announced that on December 18, 2015, it received a letter from the Nasdaq Listing Qualification Staff advising the Company that Nasdaq has determined to delist the Company's securities pursuant to its discretionary authority under Nasdaq Listing Rule 5101. Nasdaq's letter to the Company cited a number of reasons for their decision, including the recent criminal indictment and arrest of Martin Shkreli, the Company's controlling shareholder, former Chairman and former Chief Executive Officer, based on allegations of securities fraud, among other things, as well as the arrest and indictment of Evan Greebel, the Company's former outside counsel, based on similar allegations, and a civil complaint from the U.S. Securities and Exchange Commission filed against Mr. Shkreli and Mr. Greebel based on similar allegations. Nasdaq cited an additional basis for delisting based on the Company non-compliance with the filing requirements forth in the Nasdaq's Listing Rule 5250(c)(1) because it has not filed its Quarterly Report on Form 10-Q for the period ended September 30, 2015. KBIO: 11.03 (-12.56)
EQUITY ALERT: Rosen Law Firm Announces the Filing of a Securities Class Action Lawsuit Against KaloBios Pharmaceuticals, Inc. - KBIO
BusinessWire - Wed Dec 23, 2:53PM CST
Rosen Law Firm, a global investor rights law firm, announces that a class action lawsuit has been filed on behalf of purchasers of KaloBios Pharmaceuticals, Inc. (NASDAQ:KBIO) securities from November 19, 2015 through December 17, 2015, all dates inclusive (the "Class Period"
. The lawsuit seeks to recover damages for KaloBios investors under the federal securities laws. KBIO: 11.03 (-12.56)
